In situ localization of gelatinolytic activity in the extracellular matrix of metastases of colon cancer in rat liver using quenched fluorogenic DQ-gelatin

Journal of Histochemistry and Cytochemistry

Volumn 51, Issue 6, 2003, Pages 821-829

  Mook, Olaf R F ^a   Van Overbeek, Claudia ^a   Ackema, Eleonora G ^a   Van Maldegem, Febe ^a   Frederiks, Wilma M ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

DQ gelatin; Extracellular matrix; Gelatinase activity; In situ zymograpy; Matrix metalloproteinase; Metastasis

Indexed keywords

DQ GELATIN; GELATIN; GELATINASE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; CANCER INVASION; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; LIVER METASTASIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; ZYMOGRAPHY;

ANIMALIA;

EID: 0037675000     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1177/002215540305100613     Document Type: Article

References (42)

1. Baker EA, Bergin FG, Leaper DJ (2000) Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg 87:1215-1221
2. Briknarova K, Gehrmann M, Banyai L, Tordai H, Patthy L, Llinas M (2001) Gelatin-binding region of human matrix metalloproteinase-2: solution structure, dynamics, and function of the COL-23 two-domain construct. J Biol Chem 276:27613-27621
3. Collier IE, Krasnov PA, Strongin AY, Birkedal-Hansen H, Goldberg GI (1992) Alanine scanning mutagenesis and functional analysis of the fibronectin-like collagen-binding domain from human 92-kDa type IV collagenase. J Biol Chem 267:6776-6781
4. Collier IE, Wilhelm SM, Eisen AZ, Marmer BL, Grant GA, Seltzer JL, Kronberger A, et al. (1988) H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem 263:6579-6587
5. Crawford HC, Matrisian LM (1994) Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invas Metast 14:234-245
6. Creemers LB, Jansen ID, Docherty AJ, Reynolds JJ, Beertsen W, Everts V (1998) Gelatinase A (MMP-2) and cysteine proteinases are essential for the degradation of collagen in soft connective tissue. Matrix Biol 17:35-46
7. Davidson B, Goldberg I, Gorlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, Berner A, et al. (1999) High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metast 17:799-808
8. Della Porta P, Soeltl R, Krell HW, Collins K, O'Donoghue M, Schmitt M, Kruger A (1999) Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo. Anticancer Res 19:3809-3816
9. Forsyth PA, Laing TD, Gibson AW, Rewcastle NB, Brasher P, Sutherland G, Johnston RN, et al. (1998) High levels of gelatinase-B and active gelatinase-A in metastatic glioblastoma. J Neurooncol 36:21-29
10. Galis ZS, Sukhova GK, Libby P (1995) Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J 9:974-980
11. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, et al. (1994) Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 370:555-557
12. Griffini P, Smorenburg SM, Verbeek FJ, Van Noorden CJ (1997) Three-dimensional reconstruction of colon carcinoma metastases in liver. J Microsc 187:12-21
13. Heussen C, Dowdle EB (1980) Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 102:196-202
14. Himelstein BP, Canete-Soler R, Bernhard EJ, Dilks DW, Muschel RJ (1994) Metalloproteinases in tumor progression: the contribution of MMP-9. Invas Metast 14:246-258
15. Jalalah SM, Furness PN, Barker G, Thomas M, Hall LL, Bicknell GR, Shaw JA, et al. (2000) Inactive matrix metalloproteinase 2 is a normal constituent of human glomerular basement membrane. An immuno-electron microscopic study. J Pathol 191:61-66
16. Jonges GN, Vogels IM, Bosch KS, Dingemans KP, Van Noorden CJ (1993) Experimentally induced colon cancer metastases in rat liver increase the proliferation rate and capacity for purine catabolism in liver cells. Histochemistry 100:41-51
17. Knittel T, Mehde M, Grundmann A, Saile B, Scharf JG, Ramadori G (2000) Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat. Histochem Cell Biol 113:443-453
18. Koyama H, Iwata H, Kuwabara Y, Iwase H, Kobayashi S, Fujii Y (2000) Gelatinolytic activity of matrix metalloproteinase-2 and -9 in oesophageal carcinoma: a study using in situ zymography. Eur J Cancer 36:2164-2170
19. Kruger A, Soeltl R, Sopov I, Kopitz C, Arlt M, Magdolen V, Harbeck N, et al. (2001) Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res 61:1272-1275
20. Levi E, Fridman R, Miao H-Q, Ma Y-C, Yayon A, Vlodavsky I (1996) Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor I. Proc Natl Acad Sci USA 93:7069-7074
21. Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F (1996) Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 56:190-196
22. Lombard MA, Wallace TL, Kubicek MF, Petzold GL, Mitchell MA, Hendges SK, Wilks JW (1998) Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-α receptors in a human colon adenocarcinoma (Colo 205) cell line. Cancer Res 58:4001-4007
23. Marquet RL, Westbroek DL, Jeekel J (1984) Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site. Int J Cancer 33:689-692
24. Massova I, Kotra LP, Fridman R, Mobashery S (1998) Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 12:1075-1095
25. McCawley LJ, Matrisian LM (2000) Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 6:149-156
26. Meyer T, Hart IR (1998) Mechanisms of tumour metastasis. Eur J Cancer 34:214-221
27. Murphy G, Nguyen Q, Cockett MI, Atkinson SJ, Allan JA, Knight CG, Willenbrock F, et al. (1994) Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J Biol Chem 269:6632-6636
28. Nagase H, Woessner JF Jr. (1999) Matrix metalloproteinases. J Biol Chem 274:21491-21494
29. Oh LY, Larsen PH, Krekoski CA, Edwards DR, Donovan F, Werb Z, Yong VW (1999) Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. J Neurosci 19:8464-8475
30. Prontera C, Mariani B, Rossi C, Poggi A, Rotilio D (1999) Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer 81:761-766
31. Rasmussen HS, McCann PP (1997) Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 75:69-75
32. Ratnikov B, Deryugina E, Leng J, Marchenko G, Dembrow D, Strongin A (2000) Determination of matrix metalloproteinase activity using biotinylated gelatin. Anal Biochem 286:149-155
33. Ray JM, Stetler-Stevenson WG (1994) The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 7:2062-2072
34. Schonbeck U, Mach F, Libby P (1998) Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 161:3340-3346
35. Steffensen B, Wallon UM, Overall CM (1995) Extracellular matrix binding properties of recombinant fibronectin type II-like modules of human 72-kDa gelatinase/type IV collagenase. High affinity binding to native type I collagen but not native type IV collagen. J Biol Chem 270:11555-11566
36. Tarlton JF, Whiting CV, Tunmore D, Bregenholt S, Reimann J, Claesson MH, Bland PW (2000) The role of up-regulated serine proteases and matrix metalloproteinases in the pathogenesis of a murine model of colitis. Am J Pathol 157:1927-1935
37. Van Noorden CJ, Jonges TG, Van Marle J, Bissell ER, Griffini P, Jans M, Snel J, et al. (1998) Heterogeneous suppression of experimentally induced colon cancer metastasis in rat liver lobes by inhibition of extracellular cathepsin B. Clin Exp Metast 16:159-167
38. Waas ET, Lomme RMLM, DeGroot J, Wobbes Th, Hendriks T (2002) Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer 86:1876-1883
39. Weber RW, Wakley GE, Pitt D (1999) Histochemical and ultrastructural characterization of vacuoles and spherosomes as components of the lytic system in hyphae of the fungus Botrytis cinerea. Histochem J 31:293-301
40. Woessner JF Jr (1995) Quantification of matrix metalloproteinases in tissue samples. Methods Enzymol 248:510-528
41. Wylie S, MacDonald IC, Varghese HJ, Schmidt EE, Morris VL, Groom AC, Chambers AF (1999) The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells. Clin Exp Metast 17:111-117
42. Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metallo-proteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14:163-176